Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arrowhead Pharma
(NQ:
ARWR
)
22.85
+0.15 (+0.66%)
Streaming Delayed Price
Updated: 11:56 AM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arrowhead Pharma
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Arrowhead Announces First Patient Enrolled in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout
December 08, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
HC Wainwright & Co. Maintains Buy Rating for Arrowhead Pharmaceuticals: Here's What You Need To Know
December 06, 2022
Via
Benzinga
Arrowhead Pharmaceuticals Surges After Hinting At A Midstage Win In Liver Disease
November 29, 2022
The company says it plans soon to present Phase 2 results and its Phase 3 study design.
Via
Investor's Business Daily
Arrowhead Pharmaceuticals's Return On Capital Employed Overview
November 29, 2022
Via
Benzinga
Analyst Ratings for Arrowhead Pharmaceuticals
November 29, 2022
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2022 Year End Results
November 28, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Earnings Preview For Arrowhead Pharmaceuticals
November 25, 2022
Via
Benzinga
Earnings Scheduled For November 28, 2022
November 28, 2022
Companies Reporting Before The Bell • Pinduoduo (NASDAQ:PDD) is projected to report quarterly earnings at $0.65 per share on revenue of $4.31 billion.
Via
Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conferences
November 21, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Year End Results
November 14, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
November 09, 2022
From
Royalty Pharma plc
Via
GlobeNewswire
Arrowhead Sells Royalty Interest in Olpasiran to Royalty Pharma for $250 Million and Future Milestones
November 09, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Presents New Phase 2 Data at AHA 2022 on Cardiometabolic Pipeline
November 07, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 13, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Present Interim Phase 2 Clinical Data at AHA 2022 on SHASTA-2 Study of ARO-APOC3 and ARCHES-2 Study of ARO-ANG3
October 11, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Arrowhead Pharmaceuticals to Participate in Upcoming September 2022 Conferences
September 01, 2022
From
Arrowhead Pharmaceuticals Inc.
Via
Business Wire
Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MMP7 for Idiopathic Pulmonary Fibrosis
August 17, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
What 7 Analyst Ratings Have To Say About Arrowhead Pharmaceuticals
August 08, 2022
Analysts have provided the following ratings for Arrowhead Pharmaceuticals (NASDAQ:ARWR) within the last quarter:
Via
Benzinga
Arrowhead Pharmaceuticals: Q3 Earnings Insights
August 04, 2022
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q3 earnings results on Thursday, August 4, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2022 Third Quarter Results
August 04, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Third Quarter Results
July 20, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
July 08, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Initiates Phase 1/2a Studies for Two Pulmonary Candidates ARO-MUC5AC and ARO-RAGE
July 05, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals to Participate in Upcoming June 2022 Conferences
June 07, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Arrowhead Pharmaceuticals Hosts R&D Day on Emerging Pipeline of Pulmonary Targeted RNAi Therapeutics
May 26, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
Where Arrowhead Pharmaceuticals Stands With Analysts
May 24, 2022
Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022
May 11, 2022
Upgrades
Via
Benzinga
Arrowhead Pharmaceuticals: Q2 Earnings Insights
May 10, 2022
Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.
Via
Benzinga
Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results
May 10, 2022
From
Arrowhead Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.